PepGen
Boston, Massachusetts, United States · Biotechnology, Healthcare
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of
Key facts
- Headquarters
- Boston, Massachusetts, United States
- Employees
- 84
- Industries
- Biotechnology, Healthcare
- Status
- Public (PEPG)
- Website
- pepgen.com
- Company page
Recent activity at PepGen
- : SEC 8-K (1.01): On November 11, 2026, PepGen Inc. entered into a material underwriting agreement with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC, allowing the issuance and sale of 25,000,000 shares of common stock at $5.00 per share. The agreement grants underwriters a 30-day option to purchase an additional 3,750,000 shares. The estimated net proceeds from the offering are approximately $116.9 million. The offering is expected to close on November 13, 2026, pending customary closing conditions. The funds will be used for ongoing clinical development and general corporate purposes.
- : SEC 8-K (8.01): On November 10, 2026, PepGen Inc. filed a Form 8-K to disclose various events considered important to security holders. This includes a presentation titled 'FREEDOM2-DM1, 10 mg/kg MAD Cohort Data Update' which is intended for use in meetings with investors. The filing also includes two press releases dated November 10, 2026, reporting the company's third quarter financial results and positive outcomes from a Phase 2 clinical trial. The presentation and the press releases underscore the company's ongoing developments in their drug research, which could have significant implications for investor interest and market performance.
- : SEC 8-K (8.01): On August 6, 2026, PepGen Inc. announced that an independent Data and Safety Monitoring Board (DSMB) has recommended advancing the ongoing Phase 2 FREEDOM2-DM1 study into the third and highest multiple ascending dose (MAD) cohort of 12.5 mg/kg. This advancement comes with no recommended changes to the study protocol. Additionally, the DSMB recommended dose escalation in the open-label extension (OLE) study from 5 mg/kg to 10 mg/kg. The announcement could have significant implications for the drug's development pipeline and potential market approval timelines.
- : SEC 8-K (7.01): On May 21, 2026, PepGen Inc. updated its Corporate Presentation in preparation for participating in the 15th International Myotonic Dystrophy Consortium scheduled for May 26-30, 2026. This filing serves as a Regulation FD Disclosure, meaning the information is intended for public release to ensure transparency for investors. The updated Corporate Presentation is included as Exhibit 99.1 and is significant for stakeholders preparing for the upcoming event, potentially impacting investor perceptions and engagement. The company actively emphasizes that the information is furnished and should not be considered 'filed' under relevant securities legislation.
- : SEC 8-K (8.01):
- : SEC 8-K (8.01): On March 4, 2026, PepGen Inc. announced that it received a partial clinical hold notice from the U.S. Food and Drug Administration regarding its FREEDOM2-DM1 Phase 2 clinical trial of PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1). This regulatory update is significant as it may impact the trial's timeline and participant recruitment. The announcement highlights the company's ongoing efforts to advance its clinical programs and is expected to inform stakeholders about the status of their drug development pipeline.
- : SEC 8-K (7.01): On March 4, 2026, PepGen Inc. updated its Corporate Presentation, which is detailed in Exhibit 99.1 attached to this report. This update provides significant insights into the company's current operational status and strategies moving forward. The information disclosed is for regulatory compliance and will not be treated as 'filed' under certain sections of the Securities Act or Exchange Act, limiting its legal implications. This update is essential for current and potential investors to understand the company's direction and performance as of March 2026.
- : SEC 8-K (8.01): On December 8, 2025, PepGen Inc. announced the appointment of Joseph Vittiglio, Esq., as the Chief Business and Legal Officer of the Company. This change in management reflects PepGen's ongoing commitment to strengthen its leadership team in pursuit of its strategic goals. The announcement reaffirms the Company's focus on enhancing its operational and legal frameworks as it continues to navigate the competitive landscape of the biopharmaceutical industry. No specific financial compensation details were mentioned in the filing.
- : SEC 8-K (8.01): On December 8, 2025, PepGen Inc. announced the appointment of Joseph Vittiglio, Esq., as the Company’s Chief Business and Legal Officer. This change in management is significant as it brings in an experienced legal and business leader to strengthen the company's operations. The announcement was made via a press release, emphasizing the strategic direction PepGen Inc. is taking towards expanding its leadership team. This event marks an important development in the company's governance structure and may impact its future strategic initiatives.
- : SEC 8-K (5.02): On November 4, 2025, PepGen Inc.'s Board of Directors approved a repricing of underwater stock options for current employees and executive officers, including CEO James McArthur, CFO Noel Donnelly, and EVP Paul Streck. This repricing allows holders of options with exercise prices above the recent 52-week high market value to reduce their exercise price to $4.53, contingent upon remaining with the company through a specified Retention Period ending March 31, 2027, or upon a sale event. The decision was made to retain and motivate key employees during a crucial period, following a recommendation from the Compensation Committee and adhering to corporate governance standards. The repricing reflects approximately two-thirds of outstanding stock options held by employees, ensuring their alignment with shareholder interests.
PepGen funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2021 | Venture | $112.5M |
| Dec 2020 | Venture | $14.4M |
Leadership
- James McArthur, Executive Officer, Director
- Heidi Henson, Director
- Christopher Ashton, Director
- Ramin Farzaneh-Far, Director
- Joshua Resnick, Director
- Caroline Godfrey, Executive Officer, Director
- Matthew Wood, Director
- Josh Resnick, Director
- Kasra Kasraian, Chief Technology Officer
- Paul Streck, Vice President
Verified email and direct lines for PepGen’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
PepGen files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Companies similar to PepGen
- Enliven Therapeutics · Biotechnology, Healthcare
- Octave Bioscience · Biotechnology, Healthcare
- Passage Bio · Biotechnology, Healthcare
- InspireMD · Biotechnology, Healthcare
- Pelthos Therapeutics · Biotechnology, Healthcare
About PepGen: questions and answers
What does PepGen do?
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide (EDO) platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of
Where is PepGen headquartered?
PepGen is headquartered in Boston, Massachusetts, United States.
How many employees does PepGen have?
PepGen has about 84 employees.
Has PepGen raised funding?
Yes. Fundz has recorded 2 funding events for PepGen. The most recent, $112.5M, was in Aug 2021.
Who leads PepGen?
Paul Streck is a Vice President at PepGen.
What is the latest news on PepGen?
On Nov 12, 2026, SEC 8-K (1.01): On November 11, 2026, PepGen Inc. entered into a material underwriting agreement with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC, allowing the issuance and sale of 25,000,000 shares of common stock at $5.00 per share. The agreement
Is PepGen a public company?
Yes. PepGen is publicly traded under the ticker PEPG.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy